Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 18.2% in March

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totaling 58,790 shares, a drop of 18.2% from the February 26th total of 71,837 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily volume of 15,085 shares, the days-to-cover ratio is currently 3.9 days.

Exicure Trading Down 4.9%

NASDAQ:XCUR opened at $4.25 on Wednesday. The firm has a market capitalization of $27.07 million, a price-to-earnings ratio of -5.52 and a beta of 4.13. Exicure has a 1-year low of $3.10 and a 1-year high of $14.11. The business’s fifty day moving average price is $4.27 and its 200 day moving average price is $4.68.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($18.60) by $18.14.

Analyst Upgrades and Downgrades

XCUR has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. Wall Street Zen raised shares of Exicure to a “hold” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.